Clinical Trial Update: Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluated adding ipilimumab to the combination of atezolizumab and bevacizumab as first-line therapy for hepatocellular carcinoma. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: HCC - Hepatocellular Carcinoma, Metastatic Cancer | Phase 2, Phase 3 | Status: COMPLETED